EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Serum Vitamin-D, a Neuroimmunomodulator in Schizophrenic Patients: A Study at University of Ilorin Teaching Hospital.

Ishola Musbau AbdulAzeez, Adeoye Oyetunji Oyewopo, Kiblat Opeyemi ERINOSO, Abiodun Felix Omolade, Jameel Omokunmi Yusuff, Uthman Akin Hamza, Medina Bukola Bello, Sikiru Abayomi Biliaminu, Adeyinka AbdulRazaq Akande, Adekunle Bashiru Okesina, David Olusegun Awoleye, Oluwabunmi IderaOluwa Nimata Buhari

GACOPA Medical Journal · 2025

DOI: 10.71396/1v3fsx04 ↗

Kurz gefasst

Fachartikel in der Zeitschrift GACOPA Medical Journal, 2025. Verfasst von Ishola Musbau AbdulAzeez und 11 weiteren Autor:innen. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Vitamin D interacts with various pathways implicated in schizophrenia pathogenesis and independently influences the nervous and immune systems, supporting its role as a neuroimmunomodulator. AIM AND OBJECTIVE: This study assessed the relationship between serum vitamin D levels and the severity of schizophrenia and examined its correlation with disease progression in both first-episode and chronic schizophrenia patients. METHODOLOGY: This hospital-based cross-sectional study, included 50 first-episode schizophrenia patients, 50 patients with chronic schizophrenia and 50 healthy controls. Data collection employed the use of structured questionnaires to obtain socio-demographic data and a symptom severity scale (Positive and Negative Syndrome Scale) to assess the severity of the disease. Participants’ sera were obtained for serum vitamin D analysis. RESULTS: The serum Vitamin D level exhibited statistically significant and strong negative correlation with schizophrenia symptom severity among the first-episode schizophrenic group. Meanwhile, no statistically significant correlation was observed among the chronic schizophrenic participants. DISCUSSION: The study established a positive relationship between vitamin D deficiency and the severity of schizophrenia among the first-episode schizophrenic patients suggesting that vitamin D deficiency may contribute to the pathophysiology of schizophrenia and could be a modifiable risk factor for symptom management. The vitamin D levels in chronic schizophrenics could have been compensated for during the course of treatment due to family support, improved sun exposure, and diet.

Zitieren

APA

AbdulAzeez, I. M., Oyewopo, A. O., ERINOSO, K. O., Omolade, A. F., Yusuff, J. O., Hamza, U. A., Bello, M. B., Biliaminu, S. A., Akande, A. A., Okesina, A. B., Awoleye, D. O., & Buhari, O. I. N. (2025). Serum Vitamin-D, a Neuroimmunomodulator in Schizophrenic Patients: A Study at University of Ilorin Teaching Hospital. GACOPA Medical Journal. https://doi.org/10.71396/1v3fsx04

Vancouver

AbdulAzeez IM, Oyewopo AO, ERINOSO KO, Omolade AF, Yusuff JO, Hamza UA, et al. Serum Vitamin-D, a Neuroimmunomodulator in Schizophrenic Patients: A Study at University of Ilorin Teaching Hospital. GACOPA Medical Journal. 2025. doi:10.71396/1v3fsx04

BibTeX
@article{AbdulAzeez2025,
  author = {AbdulAzeez, Ishola Musbau and Oyewopo, Adeoye Oyetunji and ERINOSO, Kiblat Opeyemi and Omolade, Abiodun Felix and Yusuff, Jameel Omokunmi and Hamza, Uthman Akin and Bello, Medina Bukola and Biliaminu, Sikiru Abayomi and Akande, Adeyinka AbdulRazaq and Okesina, Adekunle Bashiru and Awoleye, David Olusegun and Buhari, Oluwabunmi IderaOluwa Nimata},
  title = {Serum Vitamin-D, a Neuroimmunomodulator in Schizophrenic Patients: A Study at University of Ilorin Teaching Hospital},
  journal = {GACOPA Medical Journal},
  year = {2025},
  doi = {10.71396/1v3fsx04}
}
Kostenlos starten →